Authors
Latest:
Ceftriaxone Dosing: Once or Twice Daily?In the latest column from SIDP, clinicians discuss that along with the once-daily dosing for many indications, there are also compelling indications for twice-daily dosing.
Latest:
Early Experience With the BioFire Pneumonia PanelA balance between antimicrobial stewardship and the search for multidrug-resistant organisms.
Latest:
Honoring Her Daughter’s Legacy After a Long-Standing Battle With Antimicrobial ResistanceAfter Diane Shader Smith lost her daughter, Mallory, to a multidrug resistant infection, she turned her personal tragedy into a mission designed to inform people about antimicrobial resistance (AMR), and have the public coalesce around this expanding medical issue.
Latest:
Ethical and Innovative Use of AI in Infectious DiseasePatient-centered innovation amidst evolving regulations and policies is a key strategy.
Latest:
Strengthening Observational Studies: Community Engagement and Data PracticesEmily Ricotta, PhD, MSc outlines the importance of involving affected populations and refining data collection methods to improve early decision-making during epidemics
Latest:
Increase in Enteroviruses Seen with Decreases in COVID-19 PrecautionsThe Centers for Disease Control and Prevention (CDC) reports the rise in pediatric acute respiratory illnesses especially as there is a decrease in hygiene measures that were previously employed during the pandemic.
Latest:
Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile InfectionsTo close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.
Latest:
The FRESH Study Tests New HIV Remission Strategy in South African WomenThumbi Ndung'u, BVM, PhD discussed the safety and partial virologic control observed in a Phase 2a trial using broadly neutralizing antibodies and vesatolimod in HIV treatment interruption.
Latest:
A Chance to Improve Hepatitis C Care for PWIDHere is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.
Latest:
Imdusiran for Chronic Hepatitis B Achieves Functional Cure in 50% of PatientsArbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.
Latest:
High-Resistance Therapy Options for Treatment-Naïve Patients With HIVJoseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.
Latest:
Resolution of Scurvy in a Patient With a Spinal Cord InjuryAt 7.1%, vitamin C deficiency in the US is rare. Unfortunately, identifying scurvy is complex, frustrating, and time-consuming for both patient and provider.
Latest:
INSTIs and Cardiovascular Outcomes: More ComplexityThe significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Latest:
Ivermectin Does Not Reach Primary Endpoint in Burkina Faso Malaria TrialSunil Parikh, MD, MPH, discusses the trial’s findings, noting no significant difference in malaria incidence (1.78 vs 1.84 cases per 100 person-weeks).
Latest:
Oral Therapeutic Options to Prevent Disease Progression From COVID-19 in an Ambulatory SettingAs the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.
Latest:
Advances in Mini Gut Organoid Models Reveal Key Insights into Norovirus ReplicationSasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.
Latest:
A Penicillin Allergy Questionnaire for Outpatient ClinicsClinicians developed an algorithm and screening questionnaire for outpatient penicillin allergy evaluation, designed to stratify patients into high- and low-risk penicillin allergy groups. Here is the sample questionnaire to consider for use in clinics.
Latest:
The Roles of Misinformation, Disinformation, and Confirmation Bias in Public Health DiscourseKatrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.
Latest:
Ready, Set, Cabenuva: Implementing Cabotegravir/RilpivirineThis novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Latest:
When Climate Change Gets Personal: The Expanding Threat of Mosquito HabitatsAs someone who lives with the long-term effects of chikungunya, Camillo Mora PhD, sees the expanding habitat of mosquitos and is concerned more people will be exposed to vector-borne illnesses and deal with not only the acute phases of these viruses but also the possibility of long-term health effects they can present.
Latest:
Unmasking the Infodemic: The Impact of COVID-19 Misinformation on Public HealthSocial media platforms, public health agencies, and communities must join forces to stop the rapid spread of false information.
Latest:
Climate Change Effects on Vector-Borne Disease: The Case of LymeWith evolving weather patterns, the natural habitat of ticks is expanding, and more people are becoming susceptible to them.
Latest:
Emerging Infectious Diseases During COVID-19In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.
Latest:
From Pathogen to Infectious Disease Diagnosis: Identifying a Novel Variant of Klebsiella PneumoniaeJose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, and his team discovered the klebsiella pneumoniae variant, KPC-31, in a patient by sequencing the entire genome through a series of different diagnostics, which not only led to identifying the strain, but to a greater understanding of its antimicrobial susceptibility.
Latest:
Doravirine and Islatravir Combination Shown to be Noninferior to Once-Daily ARTIn a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.
Latest:
Bictegravir vs Darunavir in Advanced HIV: Results from the LAPTOP TrialGeorg Behrens, MD, PhD, highlights superior virological suppression and immune recovery with bictegravir-based therapy in therapy-naïve individuals with advanced HIV disease.
Latest:
Are We at a Breaking Point for Adoption of Updated Susceptibility Interpretive Criteria?The implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.
Latest:
The Future and Resources in HCV CareExpert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
